Current Challenges and Emerging Therapies in the Treatment of Gout

References

1. DalbethN. GoslingA.L. GaffoA. AbhishekA. Gout.Lancet2021397102871843185510.1016/S0140‑6736(21)00569‑933798500
   [Google Scholar]
2. TerkeltaubR. Gout in 2006: The perfect storm.Bull. NYU Hosp. Jt. Dis.2006641-2828617121496
   [Google Scholar]
3. PuigJ.G. MartínezM.A. Hyperuricemia, gout and the metabolic syndrome.Curr. Opin. Rheumatol.200820218719110.1097/BOR.0b013e3282f4b1ed18349749
   [Google Scholar]
4. AbbottR.D. BrandF.N. KannelW.B. CastelliW.P. Gout and coronary heart disease: The framingham study.J. Clin. Epidemiol.198841323724210.1016/0895‑4356(88)90127‑83339376
   [Google Scholar]
5. De VeraM.A. RahmanM.M. BholeV. KopecJ.A. ChoiH.K. Independent impact of gout on the risk of acute myocardial infarction among elderly women: A population-based study.Ann. Rheum. Dis.20106961162116410.1136/ard.2009.12277020124358
   [Google Scholar]
6. KrishnanE. BakerJ.F. FurstD.E. SchumacherH.R. Gout and the risk of acute myocardial infarction.Arthritis Rheum.20065482688269610.1002/art.2201416871533
   [Google Scholar]
7. CronsteinB.N. TerkeltaubR. The inflammatory process of gout and its treatment.Arthritis Res. Ther.20068Suppl 1S310.1186/ar190816820042
   [Google Scholar]
8. KuoC.F. GraingeM.J. ZhangW. DohertyM. Global epidemiology of gout: Prevalence, incidence and risk factors.Nat. Rev. Rheumatol.2015111164966210.1038/nrrheum.2015.9126150127
   [Google Scholar]
9. RymalE. RizzoloD. Gout: A comprehensive review.JAAPA2014279263110.1097/01.JAA.0000453233.24754.ec25102078
   [Google Scholar]
10. JamnikJ. RehmanS. MejiaBS. de SouzaR.J. KhanT.A. LeiterL.A. WoleverT.M.S. KendallC.W.C. JenkinsD.J.A. SievenpiperJ.L. Fructose intake and risk of gout and hyperuricemia: A systematic review and meta-analysis of prospective cohort studies.BMJ Open2016610e01319110.1136/bmjopen‑2016‑01319127697882
    [Google Scholar]
11. Ben SalemC. SlimR. FathallahN. HmoudaH. Drug-induced hyperuricaemia and gout.Rheumatology201756567968827498351
    [Google Scholar]
12. KuoC.F. SeeL.C. LuoS.F. KoY.S. LinY.S. HwangJ.S. LinC.M. ChenH.W. YuK.H. Gout: An independent risk factor for all-cause and cardiovascular mortality.Rheumatology201049114114610.1093/rheumatology/kep36419933595
    [Google Scholar]
13. KawaiT. OhishiM. TakeyaY. OnishiM. ItoN. YamamotoK. KamideK. RakugiH. Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients.Hypertens. Res.201235111087109210.1038/hr.2012.9922739421
    [Google Scholar]
14. Rahimi-SakakF. MaroofiM. RahmaniJ. BellissimoN. HekmatdoostA. Serum uric acid and risk of cardiovascular mortality: A systematic review and dose-response meta-analysis of cohort studies of over a million participants.BMC Cardiovasc. Disord.201919121810.1186/s12872‑019‑1215‑z31615412
    [Google Scholar]
15. TerkeltaubR. Update on gout: New therapeutic strategies and options.Nat. Rev. Rheumatol.201061303810.1038/nrrheum.2009.23620046204
    [Google Scholar]
16. ButlerF. AlghubayshiA. RomanY. The epidemiology and genetics of hyperuricemia and gout across major racial groups: A literature review and population genetics secondary database analysis.J. Pers. Med.202111323110.3390/jpm1103023133810064
    [Google Scholar]
17. DehlinM. JacobssonL. RoddyE. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors.Nat. Rev. Rheumatol.202016738039010.1038/s41584‑020‑0441‑132541923
    [Google Scholar]
18. Chen-XuM. YokoseC. RaiS.K. PillingerM.H. ChoiH.K. Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: The national health and nutrition examination survey, 2007–2016.Arthritis Rheumatol.201971699199910.1002/art.4080730618180
    [Google Scholar]
19. ChoiH.K. MountD.B. ReginatoA.M. Pathogenesis of gout.Ann. Intern. Med.2005143749951610.7326/0003‑4819‑143‑7‑200510040‑0000916204163
    [Google Scholar]
20. TowiwatP. ChhanaA. DalbethN. The anatomical pathology of gout: A systematic literature review.BMC Musculoskelet. Disord.201920114010.1186/s12891‑019‑2519‑y30935368
    [Google Scholar]
21. MartinonF. PétrilliV. MayorA. TardivelA. TschoppJ. Gout-associated uric acid crystals activate the NALP3 inflammasome.Nature2006440708123724110.1038/nature0451616407889
    [Google Scholar]
22. DalbethN. HaskardD.O. Mechanisms of inflammation in gout.Rheumatology20054491090109610.1093/rheumatology/keh64015956094
    [Google Scholar]
23. YagnikD.R. HillyerP. MarshallD. SmytheC.D.W. KrauszT. HaskardD.O. LandisR.C. Noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages: Implications for the control of joint inflammation in gout.Arthritis Rheum.20004381779178910.1002/1529‑0131(200008)43:8<1779::AID‑ANR14>3.0.CO;2‑210943868
    [Google Scholar]
24. DuanL. ZhongJ. YangY. ZhuX. Editorial: Advances in pathogenesis and therapies of gout.Front. Immunol.202213890204
    [Google Scholar]
25. SoA.K. MartinonF. Inflammation in gout: Mechanisms and therapeutic targets.Nat. Rev. Rheumatol.2017131163964710.1038/nrrheum.2017.15528959043
    [Google Scholar]
26. DalbethN. LauterioT.J. WolfeH.R. Mechanism of action of colchicine in the treatment of gout.Clin. Ther.201436101465147910.1016/j.clinthera.2014.07.01725151572
    [Google Scholar]
27. Available from: https://www.spandidos-publications.com/10.3892/ijmm 2015
28. AkiraS. TakedaK. Toll-like receptor signalling.Nat. Rev. Immunol.20044749951110.1038/nri139115229469
    [Google Scholar]
29. BeutlerB. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases.Immunol. Rev.2009227124826310.1111/j.1600‑065X.2008.00733.x19120489
    [Google Scholar]
30. DinarelloC.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.Blood2011117143720373210.1182/blood‑2010‑07‑27341721304099
    [Google Scholar]
31. KimS.K. The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout.J. Rheum. Dis.202229314015310.4078/jrd.2022.29.3.14037475970
    [Google Scholar]
32. GalozziP. BindoliS. DoriaA. OlivieroF. SfrisoP. Autoinflammatory features in gouty arthritis.J. Clin. Med.2021109188010.3390/jcm1009188033926105
    [Google Scholar]
33. WebMDWhich medicines treat Gout?2024Available From: https://www.webmd.com/arthritis/understanding-gout-treatment
34. QurieA. PreussC.V. MusaR. Allopurinol.Treasure Island, FLStatPearls Publishing2023
    [Google Scholar]
35. Drug BankFebuxostat.2023Available From: https://go.drugbank.com/drugs/DB04854
36. SilvermanW. LocoveiS. DahlG. Probenecid, a gout remedy, inhibits pannexin 1 channels.Am. J. Physiol. Cell Physiol.20082953C761C76710.1152/ajpcell.00227.200818596212
    [Google Scholar]
37. PaddaI.S. BhattR. ParmarM. Pegloticase.Treasure Island, FLStatPearls Publishing2023
    [Google Scholar]
38. GhlichlooI. GerrietsV. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).Treasure Island, FLStatPearls Publishing2023
    [Google Scholar]
39. Drug BankPrednisolone.2024Available From: https://go.drugbank.com/drugs/DB00860
40. KostićD.A. DimitrijevićD.S. StojanovićG.S. PalićI.R. ĐorđevićA.S. IckovskiJ.D. Xanthine oxidase: Isolation, assays of activity, and inhibition.J. Chem.201520151810.1155/2015/294858
    [Google Scholar]
41. PacherP. NivorozhkinA. SzabóC. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol.Pharmacol. Rev.20065818711410.1124/pr.58.1.616507884
    [Google Scholar]
42. BoveM. CiceroA.F.G. VeronesiM. BorghiC. An evidence-based review on urate-lowering treatments: Implications for optimal treatment of chronic hyperuricemia.Vasc. Health Risk Manag.201713232810.2147/VHRM.S11508028223818
    [Google Scholar]
43. VarricaC. CarvalheiroM. Faria-SilvaC. EleutérioC. SandriG. SimõesS. Topical allopurinol-loaded nanostructured lipid carriers: A novel approach for wound healing management.Bioengineering202181219210.3390/bioengineering812019234940345
    [Google Scholar]
44. TakanoY. Hase-AokiK. HoriuchiH. ZhaoL. KasaharaY. KondoS. BeckerM.A. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.Life Sci.200576161835184710.1016/j.lfs.2004.10.03115698861
    [Google Scholar]
45. BeckerM.A. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.N Engl J Med2005353232245061
    [Google Scholar]
46. BishtM. Febuxostat: A novel agent for management of hyperuricemia in gout.Indian J Pharmaceut Sci2011736597600
    [Google Scholar]
47. MAB. Clinical gout and the pathogenesis of hyperuricemia.Arthritis Allied Cond.20052005230339
    [Google Scholar]
48. MøllerJ.V. The tubular site of urate transport in the rabbit kidney, and the effect of probenecid on urate secretion.Acta Pharmacol. Toxicol.196523432933610.1111/j.1600‑0773.1965.tb00358.x5899691
    [Google Scholar]
49. GutmanA.B. Some recent advances in the study of uric acid metabolism and gout.Bull. N. Y. Acad. Med.195127314416414812253
    [Google Scholar]
50. BritannicaProbenecid drug.2023Available From: https://www.britannica.com/science/probenecid
51. WebMDProbenecid - uses, side effects, and more .2023Available From: https://www.webmd.com/drugs/2/drug-8697/probenecid-oral/details
52. RichetteP. DohertyM. PascualE. BarskovaV. BecceF. Castañeda-SanabriaJ. CoyfishM. GuilloS. JansenT.L. JanssensH. LiotéF. MallenC. NukiG. Perez-RuizF. PimentaoJ. PunziL. PywellT. SoA. TauscheA.K. UhligT. ZavadaJ. ZhangW. TubachF. BardinT. 2016 updated EULAR evidence-based recommendations for the management of gout.Ann. Rheum. Dis.2017761294210.1136/annrheumdis‑2016‑20970727457514
    [Google Scholar]
53. National Library of MedicineLiverTox: Clinical and Research Information on Drug-Induced Liver Injury.BethesdaNational Institute of Diabetes and Digestive and Kidney Diseases2012
    [Google Scholar]
54. Mengle-GawL. HubbardR.C. KarimA. YuS. TalwalkerS. IsaksonP. A study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor.Arthritis Rheum.199740Suppl. 9S93
    [Google Scholar]
55. SutariaS. KatbamnaR. UnderwoodM. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout—a systematic review.Rheumatology200645111422143110.1093/rheumatology/kel07116632483
    [Google Scholar]
56. ThekenK.N. Variability in analgesic response to non-steroidal anti-inflammatory drugs.Prostaglandins Other Lipid Mediat.2018139637010.1016/j.prostaglandins.2018.10.00530393163
    [Google Scholar]
57. JackmanR.W. RhoadsM.G. CornwellE. KandarianS.C. Microtubule-mediated NF-κB activation in the TNF-α signaling pathway.Exp. Cell Res.2009315193242324910.1016/j.yexcr.2009.08.02019732770
    [Google Scholar]
58. KuijpersTW RaleighM KavanaghT JanssenH CalafatJ RoosD Cytokine-activated endothelial cells internalize E-selectin into a lysosomal compartment of vesiculotubular shape. A tubulin-driven process.J Immunol Baltim Md19941521050609
    [Google Scholar]
59. PaschkeS. WeidnerA.F. PaustT. MartiO. BeilM. Ben-ChetritE. Technical advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments.J. Leukoc. Biol.20139451091109610.1189/jlb.101251023901122
    [Google Scholar]
60. CronsteinB.N. MoladY. ReibmanJ. BalakhaneE. LevinR.I. WeissmannG. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.J. Clin. Invest.1995962994100210.1172/JCI1181477543498
    [Google Scholar]
61. MisawaT. TakahamaM. KozakiT. LeeH. ZouJ. SaitohT. AkiraS. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome.Nat. Immunol.201314545446010.1038/ni.255023502856
    [Google Scholar]
62. U.S. PharmacistTreatment options for gout.2023Available From: https://www.uspharmacist.com/article/treatment-options-for-gout
63. EmmersonB.T. The management of gout.N. Engl. J. Med.1996334744545110.1056/NEJM1996021533407078552148
    [Google Scholar]
64. PaulB.J. Gout: An Asia-Pacific update.Int J Rheum Dis2017204407416
    [Google Scholar]
65. PaulB.J. The role of IL-1 in gout: From bench to bedside.Rheumatology201857suppl_1i12i19
    [Google Scholar]
66. JamesR. PaulB.J. New and emerging therapies in gout.Rheumatol. Autoimmun.202332707710.1002/rai2.12064
    [Google Scholar]
67. EdwardsN.L. Emerging therapies for gout.Rheum Dis Clin North Am2014403237587
    [Google Scholar]
68. MarchettiC. SwartzwelterB. GamboniF. NeffC.P. RichterK. AzamT. CartaS. TengesdalI. NemkovT. D’AlessandroA. HenryC. JonesG.S. GoodrichS.A. St LaurentJ.P. JonesT.M. ScribnerC.L. BarrowR.B. AltmanR.D. SkourasD.B. GattornoM. GrauV. JanciauskieneS. RubartelliA. JoostenL.A.B. DinarelloC.A. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.Proc. Natl. Acad. Sci. USA20181157E1530E153910.1073/pnas.171609511529378952
    [Google Scholar]
69. KlückV. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.Lancet Rheumatol202025e270e280
    [Google Scholar]
70. JoostanL.A.B. Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra.Ann Rheum Dis20167561219e280
    [Google Scholar]
71. SattuiS.E. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications.Ther Adv Musculoskelet Dis.201684145159
    [Google Scholar]
72. ShahidH. Investigational drugs for hyperuricemia.Expert Opin Investig Drugs2015248101330
    [Google Scholar]
73. BarafH.S.B. LB0002 safety & efficacy of sel-212 in patients with gout refractory to coventional treatment: Outcomes from two randomized, double blind, placebo-controlled, multicenter phase III studies.BMJ2015821200.2
    [Google Scholar]
74. DalbethN. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: Findings of a phase III clinical trial.Arthritis Rheumatol.20176991903
    [Google Scholar]
75. HosoyaT. SanoT. SasakiT. FushimiM. OhashiT. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.Clin. Exp. Nephrol.202024Suppl. 1627010.1007/s10157‑020‑01849‑031980978
    [Google Scholar]
76. DaviesM.J. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.Diabetes Obes Metab.2015174426
    [Google Scholar]
77. PascartT. RichetteP. Investigational drugs for hyperuricemia, an update on recent developments.Expert Opin. Investig. Drugs201827543744410.1080/13543784.2018.147113329718730
    [Google Scholar]
78. DaviesM.J. Tuna extract reduces serum uric acid in gout-free subjects with insignificantly high serum uric acid: A randomized controlled trial.Biomed Rep. 201652254
    [Google Scholar]
79. DaoussisD. BogdanosD.P. DimitroulasT. SakkasL. AndonopoulosA.P. Adrenocorticotropic hormone: An effective “natural” biologic therapy for acute gout?Rheumatol. Int.202040121941194710.1007/s00296‑020‑04659‑532715340
    [Google Scholar]
80. DaoussisD ACTH as a treatment for acute crystal-induced arthritis: update on clinical evidence and mechanisms of action.Semin Arthritis Rheum2014435648
    [Google Scholar]
81. ChoiY Effect of fenofibrate on uric acid level in patients with gout.Sci. Rep.2018835175
    [Google Scholar]
82. LeeY.H. LeeC.H. LeeJ. Effect of fenofibrate in combination with urate lowering agents in patients with gout.Korean J. Intern. Med.2006212899310.3904/kjim.2006.21.2.8916913436
    [Google Scholar]
83. NakashimaM. UematsuT. KosugeK. KanamaruM. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects.Eur. J. Clin. Pharmacol.199242333333510.1007/BF002663581577054
    [Google Scholar]
84. ShahinfarS Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.Kidney Int19995651879
    [Google Scholar]
85. ChanardJ Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients.Nephrol Dial Transplant200318102147
    [Google Scholar]
86. MilionisH.J. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.Am Heart J20041484402147
    [Google Scholar]
87. ZhuR. NiuY. ZhouW. WangS. MaoJ. GuoY. LeiY. XiongX. LiY. GuoL. Effect of nanoparticles on gouty arthritis: A systematic review and meta-analysis.BMC Musculoskelet. Disord.202324112410.1186/s12891‑023‑06186‑336788552
    [Google Scholar]
88. Najahi-MissaouiW. Safe nanoparticles: Are we there yet?Int. J. Mol. Sci.2021221385
    [Google Scholar]
89. De JongW.H. Drug delivery and nanoparticles: Applications and hazards.Int J Nanomedicine200832133
    [Google Scholar]
90. KiyaniM.M. Evaluation of antioxidant activity and histopathological changes occurred by the oral ingestion of CuO nanoparticles in monosodium urate crystal-induced hyperuricemic BALB/c mice. Biol Trace Elem Res20222001217
    [Google Scholar]
91. KiyaniM.M. Antioxidant and anti-gout effects of orally administered zinc oxide nanoparticles in gouty mice.J Trace Elem Med Biol201956169
    [Google Scholar]
92. ChenY. Superparamagnetic iron oxide nanoparticles protect human gingival fibroblasts from Porphyromonas gingivalis invasion and inflammatory stimulation.Int J Nanomedicine20221745
    [Google Scholar]
93. ChenY. Evaluation of turmeric nanoparticles as anti-gout agent: Modernization of a traditional drug.Medicina2019551711045
    [Google Scholar]
94. WangS. ZhangY. KongH. ZhangM. ChengJ. WangX. LuF. QuH. ZhaoY. Antihyperuricemic and anti-gouty arthritis activities of Aurantii fructus immaturus carbonisata-derived carbon dots.Nanomedicine201914222925293910.2217/nnm‑2019‑025531418646
    [Google Scholar]
95. RahmiE.P. KumolosasiE. JalilJ. HusainK. BuangF. Anti-hyperuricemic and anti-inflammatory effects of Marantodes pumilumas potential treatment for gout.Front. Pharmacol.20201100289
    [Google Scholar]
96. XieH. Puerarin alleviates vincristine-induced neuropathic pain and neuroinflammation via inhibition of nuclear factor-κB and activation of the TGF-β/Smad pathway in rats.Int Immunopharmacol202089Pt B107060
    [Google Scholar]
97. LiuY. ZhuH. ZhouW. YeQ. Anti-inflammatory and anti-gouty-arthritic effect of free Ginsenoside Rb1 and nano Ginsenoside Rb1 against MSU induced gouty arthritis in experimental animals.Chem. Biol. Interact.202033210928510.1016/j.cbi.2020.10928533038330
    [Google Scholar]
98. ZhangJ. SunY. QuQ. LiB. ZhangL. GuR. ZuoJ. WeiW. MaC. LiuL. LiuK. LiJ. ZhangH. Engineering non-covalently assembled protein nanoparticles for long-acting gouty arthritis therapy.J. Mater. Chem. B Mater. Biol. Med.20219489923993110.1039/D1TB01760H34842263
    [Google Scholar]
99. HaoY. LiH. CaoY. ChenY. LeiM. ZhangT. XiaoY. ChuB. QianZ. Uricase and horseradish peroxidase hybrid CaHPO4 nanoflower integrated with transcutaneous patches for treatment of hyperuricemia.J. Biomed. Nanotechnol.201915595196510.1166/jbn.2019.275230890227
    [Google Scholar]